Last updated on May 2017

A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects with Candidemia (STRIVE)


Brief description of study

A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects with Candidemia (STRIVE)

Detailed Study Description

Candidemia is an infection of the blood caused by the fungus, Candida. The study drug, CD101, is being studied to treat candidemia. This is the first research study in which CD101 will be given to patients with candidemia. CD101 is an experimental or investigational drug. In this research study, CD101 will be compared to other drugs, caspofungin, followed by fluconazole. Caspofungin and fluconazole are drugs that are approved by the FDA and EMA and are used for the treatment of candidemia.

Clinical Study Identifier: TX149297

Contact Investigators or Research Sites near you

Start Over

Reading Hospital Clinical Trials Office

Reading Hospital Clinical Trials Office
West Reading, PA USA
  Connect »